Quick Answer
Co-Diagnostics, Inc. reported Operating Income Loss of -$50.17 million for the year ending 2025.
- Co-Diagnostics, Inc. showed a decrease of -25.2% in Operating Income Loss from 2024 to 2025.
- This data is from Co-Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$390.3 thousand | Q3 2016: -$392.4 thousand | Q1 2017: -$564.4 thousand | Q2 2017: -$701.0 thousand | Q3 2017: -$1.81 million | Q1 2018: -$1.28 million | Q2 2018: -$1.35 million | Q3 2018: -$1.66 million | Q1 2019: -$1.25 million | Q2 2019: -$1.37 million | Q3 2019: -$1.65 million | Q1 2020: -$1.08 million | Q2 2020: $14.71 million | Q3 2020: $12.04 million | Q1 2021: $10.33 million | Q2 2021: $11.79 million | Q3 2021: $13.63 million | Q1 2022: $9.82 million | Q2 2022: -$4.15 million | Q3 2022: -$6.54 million | Q1 2023: -$9.95 million | Q2 2023: -$11.99 million | Q3 2023: -$8.94 million | Q1 2024: -$10.26 million | Q2 2024: -$7.68 million | Q3 2024: -$10.23 million | Q1 2025: -$8.55 million | Q2 2025: -$8.06 million | Q3 2025: -$7.01 million.
- Over the full 10 years of available data (2016 to 2025), Co-Diagnostics, Inc.'s Operating Income Loss has declined by 2,871.9%.
- Historical annual values: Fiscal year 2025: -$50.17 million | Fiscal year 2024: -$40.08 million | Fiscal year 2023: -$42.71 million | Fiscal year 2022: -$26.98 million | Fiscal year 2021: $46.06 million | Fiscal year 2020: $41.69 million | Fiscal year 2019: -$5.89 million | Fiscal year 2018: -$6.12 million | Fiscal year 2017: -$4.56 million | Fiscal year 2016: -$1.69 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: